MedTrace Logo

The Role of Biomarker in Serum, Cerebrospinal Fluid and Parenchyma in the Context of Aneurysmal Subarachnoid Hemorrhage.

NCT02142166 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 310

Last updated 2020-02-05

No results posted yet for this study

Summary

The aim of this study is to improve the usability of biomarkers for the timely prediction of new complications following a cerebral hemorrhage, especially in combination with invasive, functional and local measurements for patients with aneurysmal subarachnoid hemorrhage (SAH). Based on analyzed biomarker profiles the chosen therapy efforts are assessed in their immediate and longer-term effectiveness.

Conditions

  • Aneurysmal Subarachnoid Hemorrhage

Interventions

PROCEDURE

Biomarker in serum, liquor, micro-dialysate

Daily (21 days) analysis of biomarker in serum, in liquor and in micro-dialysate

PROCEDURE

Biomarker in serum and in liquor

Single analysis of biomarker in serum and liquor

Sponsors & Collaborators

  • RWTH Aachen University

    lead OTHER

Principal Investigators

  • Walid Albanna, Priv.-Doz. Dr. med. · Department of Neurosurgery, University Hospital RWTH Aachen

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02142166 on ClinicalTrials.gov